CD44 drives aggressiveness and chemoresistance of a metastatic human osteosarcoma xenograft model

// Lisa Mayr 1 , Christine Pirker 1 , Daniela Lötsch 1 , Sushilla Van Schoonhoven 1 , Reinhard Windhager 2 , Bernhard Englinger 1 , Walter Berger 1 and Bernd Kubista 2 1 Institute of Cancer Research and Comprehensive Cancer Center, Department of Medicine I, Medical University Vienna, 1090 Vienna, Austria 2 Department of Orthopaedics, Medical University Vienna, 1090 Vienna, Austria Correspondence to: Bernd Kubista, email: bernd.kubista@meduniwien.ac.at Keywords: CD44; osteosarcoma; metastasis; metastatic model; cilengitide Received: May 05, 2017 Accepted: November 28, 2017 Published: December 09, 2017 ABSTRACT Background: Osteosarcoma is the most common primary malignant bone tumor with a 5 year survival rate of up to 70%. However, patients with metastatic disease have still a very poor prognosis. Osteosarcoma metastasis models are essential to develop novel treatment strategies for advanced disease. Methods: Based on a serial transplantation approach, we have established a U-2 OS osteosarcoma xenograft model with increased metastatic potential and compared it to other metastatic osteosarcoma models from international sources. Subclones with differing invasive potential were compared for genomic gains and losses as well as gene expression changes by several bioinformatic approaches. Based on the acquired results, the effects of a shRNA-mediated CD44 mRNA knockdown on migration, invasion and chemosensitivity were evaluated. Results: The CD44 gene was part of an amplified region at chromosome 11p found in both U-2 OS subclones with enhanced metastatic potential but not in parental U-2 OS cells, corresponding with distinct CD44 overexpression. Accordingly, shRNA-mediated CD44 knockdown significantly attenuated osteosarcoma cell migration, invasion, and viability especially in the metastatic subclones of U-2 OS and Saos-2 cells. Metastatic subclones generally were hypersensitive against the integrin inhibitor cilengitide paralleled by alterations in integrin expression pattern following CD44 knock-down. Additionally, attenuation of CD44 expression sensitized these cell models against osteosarcoma chemotherapy with doxorubicin but not methotrexate and cisplatin. Conclusions: The osteosarcoma xenograft models with increased metastatic potential developed in this study can be useful for identification of mechanisms driving metastasis and resistance towards clinically used and novel therapeutic regimens.